Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Spiridonidis, C.H.
Right arrow Articles by Kuebler, J.Ph.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spiridonidis, C.H.
Right arrow Articles by Kuebler, J.Ph.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:89-94, 2001
© 2001 European Society for Medical Oncology

research-article

Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: A phase II trial

C.H. Spiridonidis1, L.R. Laufman1, L. Carman2, T. Moore3, S. Blair4, J. Jones5, Ch. George4, T. Patel3, R. Roach3, R. Rupert6, J. Zangmeister3, D. Colborn2 and J.Ph. Kuebler4

1Hematology Oncology Consultants Incorporated Columbus, Ohio Newark
2Columbus Community Clinical Oncology Program Columbus, Ohio Newark
3Mid-Ohio Oncologv Group Columbus, Ohio Newark
4Columbus Oncology Associates Columbus, Ohio Newark
5Licking Memorial Hospital Professional Corporation Newark
6University Hospitals East Columbus, Ohio, USA

C H Spiridomdis, MD Hematology Oncology Consultants Incorporated 393 East TownStreet, Suite 109 Columbus, OH 43215 USA E-mail hspindom{at}aol.com

BACKGROUND: Docetaxel and gemcitabine are active against chemotherapy-pretreated non-small-cell lung cancer (NSCLC). The purpose of this phase II study was to evaluate the efficacy and safety of monthly docetaxel combined with weekly gemcitabine in NSCLC patients failing one prior regimen

PATIENTS AND METHODS: Forty patients were enrolled Prior chemotherapy was a platinum-based combination in 36 patients, using vinorelbine in 26 patients and etoposide in 10 patients The other four patients had prior single agents Tumors were refractory or resistant to front-line therapy in 80%of patients Treatment was gemcitabine 800 mg/m2days I, 8, 15 and docetaxel 100 mg/m2 day 1, with cycles repeated every four weeks

RESULTS: Thirteen patients responded (32 5% 95%confidence interval CI) 19%—49%), including one complete and 12partial responses. Responses were observed at all metastatic sites, with similar response frequencies in platinum-sensitive and platinum-resistant/refractory tumors The median time to progression for responders was nine months,with two responses lasting longer than a year Median survival was 8.1 months Hematologic toxicities included grade 4 neutropenia in 23 patients, with 4 episodes of febrile neutropenia, grade3–4 thrombocytopenia in 9 patients, and anemia requiring red cell transfusions in 9 patients. With the exception of asthenia, severe non-hematologic toxicities were infrequent

CONCLUSIONS: Monthly docetaxel, combined with weekly gemcitabine,is an active and safe second-line therapy for NSCLC patients

docetaxel for NSCLC, second-line gemcitabine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
K. Takeda, S. Negoro, T. Tamura, Y. Nishiwaki, S. Kudoh, S. Yokota, K. Matsui, H. Semba, K. Nakagawa, Y. Takada, et al.
Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)
Ann. Onc., May 1, 2009; 20(5): 835 - 841.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Matsui, T. Hirashima, T. Nitta, M. Kobayashi, Y. Ogata, M. Furukawa, S. Kudoh, N. Yoshimura, T. Mukohara, S. Yamauchi, et al.
A Phase I/II Study Comparing Regimen Schedules of Gemcitabine and Docetaxel in Japanese Patients with Stage IIIB/IV Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., April 1, 2005; 35(4): 181 - 187.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al.
American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003
J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S.-Y. Song, W. S. Kim, K. Kim, C. W. Jung, Y. H. Im, H. J. Kim, W. K. Kang, H. G. Lee, O J. Kwon, C. H. Rhee, et al.
Vinorelbine, Ifosfamide, and Cisplatin Combination as Salvage Chemotherapy in Advanced Non-Small Cell Lung Cancer
Jpn. J. Clin. Oncol., October 1, 2003; 33(10): 509 - 513.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.